Metabolic syndrome poses an elevated risk of developing chronic cardiovascular disease, type II diabetes, heart disease and stroke, which can significantly reduce quality and length of life. Moreover, these diseases have witnessed a substantial surge, prompting a notable upswing in the focus on metabolic health in recent times. Presently, there are no universally established treatments available for metabolic syndrome.

The significance of the gut microbiota in metabolic health has gained considerable attention, as studies have elucidated its link to body weight. Probiotics, like L. paracasei 8700:2®, possess the ability to modify the gut microbiota and influence the mechanisms related to metabolic health.

Over a period of three months the study, which included 130 subjects with metabolic syndrome, investigated the outcome of a daily intake of Probiˈs proprietary strain L. paracasei 8700:2® on factors relating to cardiac health, blood lipids and body weight. The study concluded that a daily intake of L. paracasei 8700:2® for 12 weeks significantly decreased the risk of cardiovascular disease and was able to counteract bodyweight gain and increased BMI.

"The significant impact on metabolic components in subjects with metabolic syndrome, even without dietary restrictions or changes in physical exercise is very promising," says Christina Vegge, Director of Discovery & Clinical Research at Probi. "The data showed improved endothelial function, lipid profile, blood sugar regulation, reduced bodyweight gain, and prevented elevated BMI compared to the placebo group," adds Vegge.

"Metabolic health is of strategic importance to Probi, and we acknowledge the significant potential of this health area to have a positive impact on numerous lives. People are experiencing longer lifespans, but their overall quality of life and health are declining. Our focus is now to explore further how our probiotic can support metabolic health and potentially reduce the risk of cardiovascular disease and in that way enhance peoples' number of years spent in good health" says Anita Johansen, CEO of Probi.

The study "Cardiometabolic benefits of Lacticaseibacillus paracasei 8700:2: a randomized double-blind placebo-controlled trial" is in press for publication in Clinical Nutrition (2023) and can be found here: Cardiometabolic benefits of Lacticaseibacillus paracasei 8700:2: a randomized double-blind placebo-controlled trial - Clinical Nutrition (clinicalnutritionjournal.com) (https://www.clinicalnutritionjournal.com/article/S0261-5614(23)00243-1/fulltext#%20)

For further information, please contact:

Anita Johansen, CEO, Probi,

Phone: +46 46 286 89 48, E-mail: anita.johansen@probi.com

ABOUT PROBI

Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for supplements and functional food. We are experts at managing stable, live bacteria from R&D through every stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden's Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally. Probi had sales of SEK 618 m in 2022. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,700 shareholders on December 31, 2022.